ArticlePediatric nephrology (Berlin, Germany)2007
Cystatin C is associated with cardiovascular risk factors and metabolic syndrome in Aboriginal youth.
Article in Pediatric nephrology (Berlin, Germany), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 44 citations in OpenAlex.
- Article
- Association of cystatin C levels with metabolic syndrome incidence: a nested case-control study with propensity score matching.The Journal of international medical research · 2021Article
- Clinical utility of serum cystatin C for prediction of multi-vessel disease by coronary angiography in type 2 diabetes mellitus patients with normal renal function.BMC cardiovascular disorders · 2020Article
- Body mass index and early kidney function decline in young adults: a longitudinal analysis of the CARDIA (Coronary Artery Risk Development in Young Adults) study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2014Article
- Comparison of CKD-EPI Cystatin C and Creatinine Glomerular Filtration Rate Estimation Equations in Asian Indians.International journal of nephrology · 2014Article
- Cystatin C and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate.Cardiovascular diabetology · 2012Article
- Implications for kidney disease in obese children and adolescents.Pediatric nephrology (Berlin, Germany) · 2011Article
- Cystatin C, cardiometabolic risk, and body composition in severely obese children.Pediatric nephrology (Berlin, Germany) · 2011Article
- Exercise electrocardiographic responses and serum cystatin C levels among metabolic syndrome patients without overt diabetes mellitus.Vascular health and risk management · 2011Article
- Lower HDL-C and apolipoprotein A-I are related to higher glomerular filtration rate in subjects without kidney disease.Journal of lipid research · 2010Article
- Relationship between cystatin C and coronary artery atherosclerosis progression differs by type 1 diabetes.Diabetes technology & therapeutics · 2010Article
- Association of cystatin C with adverse outcomes.Current opinion in nephrology and hypertension · 2009Review
- Association of visceral and subcutaneous adiposity with kidney function.Clinical journal of the American Society of Nephrology : CJASN · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Serum concentration of cystatin C, a marker of glomerular filtration, has been associated with incident cardiovascular disease (CVD), although the pathophysiology underlying this association remains unclear. As North American Aboriginal populations are experiencing high prevalence rates of CVD in early adulthood, evaluation of cardiovascular (CV) risk factors in Aboriginal children may provide insight into the early pathophysiology of vascular disease. In this context, we sought to determine whether cystatin C is associated with CV risk factors in Aboriginal youth. Serum concentrations of cystatin C were assessed in a population-based study of a Canadian Aboriginal community, involving 230 children aged 10-19 years. Cystatin C was higher in the 41 children with pediatric metabolic syndrome (MetS) (defined using an age- and gender-specific version of Adult Treatment Panel III criteria) than in the 189 children free of MetS (0.87 vs 0.81 mg/l, p = 0.0026). After adjustment for age, gender, and glomerular filtration rate (estimated using the Schwartz formula), cystatin C was (1) positively correlated with waist circumference, body mass index, systolic blood pressure, triglycerides, fasting insulin, and leptin (all r >/= 0.18, p < 0.05), and (2) inversely related to high-density lipoprotein (HDL) cholesterol (r = -0.21, p = 0.0023). These associations, however, were attenuated with further adjustment for insulin resistance, as measured by the homeostasis model assessment (HOMA-IR). On multivariate analysis, waist circumference emerged as a positive independent determinant of cystatin C, whereas female gender and age were negative correlates. Cystatin C levels progressively increased in association with the number of metabolic syndrome component disorders coexistent within an individual (trend p = 0.0072). In summary, increased cystatin C is associated with an enhanced CV risk factor profile in Aboriginal youth and may be an early event in the natural history of vascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.